Iñaki Ochandiano Recio

Dr. Iñaki Ochandiano Recio

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2024 in Brain Sciences
Verified
Journal Article
Open access
PDF file
AGAnna Giménez-Palomo
Anna Giménez-Palomo
HAHelena Andreu
Helena Andreu
OVOscar de Juan Viladegut
Oscar de Juan Viladegut
LOLuis Olivier
Luis Olivier
IRIñaki Ochandiano Recio
Iñaki Ochandiano Recio
IPIsabella Pacchiarotti
Isabella Pacchiarotti
Mitochondria are organelles involved in different cellular functions, especially energy production. A relationship between mitochondrial dysfunction and mood disorders, especially bipolar disorder (BD), has been reported in the scientific literature, which suggests altered energy production and higher levels of oxidative stress compared to healthy controls. Specifically, in BD, the hypothesis of a biphasic pattern of energy availability has been postulated according to mood states. Current evidence highlights the presence of mitochondrial dysfunction in BD and variations between the manic, depressive, and euthymic phases. These findings need to be confirmed in future studies to identify biomarkers that may lead to individualized management of patients with BD and also to identify profiles with a higher risk of presenting an unfavorable course of illness, which would enable the design of preventive and therapeutic strategies in determined subpopulations of patients with BD. The limitations of this review include the non-systematic methodology, variety of mitochondrial-related functions associated with BD, heterogeneous study designs, preliminary evidence for specific findings, and limited recommendations regarding the use of mitochondrial modulators in BD.

1 May 2025 in Acta Psychiatrica Scandinavica
Verified
Journal Article
Closed access
IRIñaki Ochandiano Recio
Iñaki Ochandiano Recio
SSSergi Salmerón
Sergi Salmerón
HAHelena Andreu
Helena Andreu
LOLuis Olivier
Luis Olivier
OJOscar de Juan
Oscar de Juan
IPIsabella Pacchiarotti
Isabella Pacchiarotti

16 May 2024 in Revista de Psiquiatría Infanto-Juvenil
Verified
Journal Article
Open access
PDF file
SSSergi Salmeron
Sergi Salmeron
JMJuan Ignacio Mena
Juan Ignacio Mena
ECEduard Cesari
Eduard Cesari
IRIñaki Ochandiano Recio
Iñaki Ochandiano Recio
MLMaria Llobet
Maria Llobet
IBInmaculada Baeza
Inmaculada Baeza
The use of long-acting injectable antipsychotics in the pediatric and adolescent population has emerged as a therapeutic approach of increasing importance in the treatment of psychotic and behavioral disorders in children and adolescents in recent years. However, due to the unique characteristics of this population, which limit the performance of large-scale studies, the available information remains limited. Nevertheless, case studies have provided valuable descriptions of their use in a variety of psychiatric disorders. In this context, we present the case of a 12-year-old male with severe behavioral disturbances who simultaneously exhibited a rare microdeletion on chromosome 18p11.32-18p11.31. In the article, we detail his clinical evolution and treatment with long-acting aripiprazole, shedding light on the applicability of this formulation in complex clinical situations. El empleo de antipsicóticos inyectables de liberación prolongada en la población infantojuvenil ha emergido como un enfoque terapéutico de creciente importancia en el tratamiento de trastornos psicóticos y del comportamiento en niños y adolescentes en los últimos años. No obstante, debido a las particularidades de esta población, que restringen la realización de estudios a gran escala, la información disponible sigue siendo limitada. A pesar de ello, estudios de casos han proporcionado valiosas descripciones de su uso en una variedad de trastornos psiquiátricos. En este contexto, presentamos el caso de un varón prepúber de 12 años con graves alteraciones conductuales, que a la par exhibía una rara microdeleción en el cromosoma 18p11.32-18p11.31. En el artículo, detallamos su evolución clínica y su tratamiento con aripiprazol de liberación prolongada, que se inició a los 10 años de edad, lo que arroja luz sobre la aplicabilidad de esta formulación en situaciones clínicas complejas.